GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced Mayo Clinic has committed $1.75M as a lead investor in a $7 million convertible note financing round.
{iframe}https://www.businesswire.com/news/home/20200805005067/en/Adaptive-Phage-Therapeutics-Announces-Mayo-Clinic-Lead{/iframe}